RhumbLine Advisers
PRME icon

RhumbLine Advisers’s Prime Medicine PRME Stock Holding History

RhumbLine Advisers’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$398K Buy
114,269
+5,860
+5% +$22.3K ﹤0.01% 2748
2025
Q4 		$376K Sell
108,409
-1,378
-1% -$6.13K ﹤0.01% 2834
2025
Q3 		$608K Buy
109,787
+11,815
+12% +$48K ﹤0.01% 2562
2025
Q2 		$242K Buy
97,972
+16,072
+20% +$24.8K ﹤0.01% 3123
2025
Q1 		$163K Buy
81,900
+9,944
+14% +$25.4K ﹤0.01% 3207
2024
Q4 		$210K Buy
71,956
+1,909
+3% +$6.7K ﹤0.01% 3170
2024
Q3 		$271K Sell
70,047
-60
-0.1% -$278 ﹤0.01% 3077
2024
Q2 		$360K Buy
70,107
+17,595
+34% +$107K ﹤0.01% 2890
2024
Q1 		$368K Buy
52,512
+1,654
+3% +$12.5K ﹤0.01% 2852
2023
Q4 		$451K Sell
50,858
-101
-0.2% -$778 ﹤0.01% 2725
2023
Q3 		$486K Buy
50,959
+3,896
+8% +$50.6K ﹤0.01% 2628
2023
Q2 		$689K Buy
+47,063
New +$657K ﹤0.01% 2496

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

RhumbLine Advisers's PRME Position: Q1 2026 in Review

RhumbLine Advisers increased its Prime Medicine (PRME) stake by 5.4% in Q1 2026, buying an estimated $22.3K and bringing the position to 114,269 shares worth $398K. The position accounts for ﹤0.01% of the portfolio, ranked #2748.

RhumbLine Advisers first reported a position in PRME in Q2 2023 and has held it in 12 quarters since. The position peaked at $689K in Q2 2023. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • RhumbLine Advisers held 114,269 shares of Prime Medicine worth $398K as of Q1 2026.
  • RhumbLine Advisers bought 5,860 Prime Medicine shares in Q1 2026, an estimated $22.3K.
  • Prime Medicine made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2748 holding.
  • RhumbLine Advisers first reported a position in Prime Medicine in Q2 2023 and has held it in 12 quarters since.
  • RhumbLine Advisers's Prime Medicine position peaked at $689K in Q2 2023.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.